Fatigue is a symptom, not a diagnosis of low growth hormone. If low energy persists despite reasonable rest or is affecting everyday activities, arrange a clinical evaluation. A peptide advertisement cannot determine whether the cause is sleep, a medicine, an illness, or another factor.

Sermorelin marketing often includes energy and recovery claims. The sources reviewed here do not establish that a particular compounded preparation reliably treats unexplained fatigue. The first useful question is what is causing the symptom, followed by which treatment has evidence for that cause.

The considered take

Describe the fatigue and investigate its cause. A promise of energy is not enough to establish the right treatment.

Describe what low energy means in your day

Feeling sleepy, lacking stamina, and having muscle weakness are different experiences. Tell the clinician whether you doze off, feel exhausted without sleepiness, or cannot perform an activity because of weakness or breathlessness. Give a concrete example, such as a change in your ability to complete a familiar walk or household task.

Record when it began, whether it is constant or episodic, and what makes it better or worse. If severe new symptoms such as chest pain, marked breathing difficulty, fainting, or confusion accompany it, seek urgent care rather than waiting for a routine wellness consultation.

Sources: MedlinePlus: Fatigue · FDA: Managing the benefits and risks of medicines

Several common explanations may need consideration

MedlinePlus lists causes including anemia, thyroid conditions, sleep disorders, mood-related conditions, medicines, and other illnesses. The clinician's assessment determines which are plausible for you and what testing is useful. A broad hormone panel is not automatically the best first investigation.

Bring a current medication list, your sleep pattern, recent illnesses, and any relevant existing results. Do not stop a medicine because fatigue appears on its side-effect list. The thyroid guide and medication-review guide help organize two parts of that conversation.

Sources: MedlinePlus: Fatigue · NIDDK: Hypothyroidism · FDA: Drug interactions, what you should know

Ask what evidence supports an energy claim

Improved IGF-1, increased fat-free mass, and better everyday energy are different outcomes. A study showing one should not be presented as proof of the others. The exact drug and population matter too: research on tesamorelin or MK-677 does not establish the performance of a compounded sermorelin prescription.

The benefits guide and clinical-studies article show how to inspect the claim. Ask the clinician whether a diagnosis supports the proposal and what outcome would demonstrate that the treatment is useful to you.

Sources: Endotext: Growth Hormone and Aging · Nass et al.: MK-677 randomized trial in older adults · GHRH, cognition and brain connectivity: pilot trial (2026)

Follow up on function, not just the refill schedule

Agree on a review point and a practical way to describe change. Keep track of the activity or symptom that prompted the visit, along with any new problems. If the hoped-for benefit does not occur, a reassessment should consider the original explanation as well as the treatment.

Do not assume that persistent fatigue means you need a larger amount or another peptide. Our not-working guide covers that discussion. If daytime sleepiness, snoring, or breathing pauses are part of the picture, read the sleep-apnea article and bring those observations to the appointment.

Sources: FDA: Managing the benefits and risks of medicines · NHLBI: Sleep apnea symptoms

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. MedlinePlus: FatigueUS National Library of Medicine · Fatigue has many causes that may need evaluation.
  2. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
  3. NIDDK: HypothyroidismNIH patient education · Symptoms, diagnosis and established thyroid treatment; not a sermorelin trial.
  4. FDA: Drug interactions, what you should knowUS regulator · General medicine, food and supplement interaction principles, not an exhaustive sermorelin interaction list.
  5. Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.
  6. Nass et al.: MK-677 randomized trial in older adultsPrimary or authoritative reference · Human randomized trial; ibutamoren is not sermorelin.
  7. GHRH, cognition and brain connectivity: pilot trial (2026)Human placebo-controlled pilot study · 22 participants and ten weeks of tesamorelin. No significant direct changes in study measures; exploratory analyses do not establish clinical benefit.
  8. NHLBI: Sleep apnea symptomsNIH patient education · Sleep-related breathing symptoms and evaluation.